Supplementary Table S3 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table S3. Safety evaluation of all adverse events and relation to treatment.
Authors: Els M.E. Verdegaal, Anique L.C. Verpoorte, Monique K. van der Kooij, Linda de Bruin, Marten Visser, Caroline E. van der Minne, Vera Weeda, Inge C.F.M. Roozen, Mare A. Jonker, Inge M. Westra, Pauline Meij, Frank M. Speetjens, Stephanie M. Zunder, Gerrit-Jan Liefers, Saskia J. Santegoets, Sjoerd H. van der Burg, Ellen H.W. Kapiteijn
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4411908249